CTT Pharma Advances Micelle Thin-Film Technology Toward 2026 Commercialization

CTT Pharma CEO Ryan Khouri detailed the company's strategy to progress its patented micelle thin-film technology toward manufacturing and commercialization in a shareholder letter. The company is preparing to file an S-1 registration statement to access funding from an equity line and transition to an SEC reporting company, a step anticipated to enhance transparency and draw greater investor interest. The capital secured will be allocated toward manufacturing the company's oral dissolvable strip products, which include micelle-encapsulated vitamins, bioactive supplements, and nicotine strips, with production aimed for 2026. Khouri stressed prudent management of share count and dilution throughout this financing phase.

CTT Pharma is currently bolstering its team with regulatory specialists to manage approval processes for North American sales and intends to recruit additional staff with experience in commercial product launches. The company is also in the process of selecting a manufacturing facility in the first quarter, followed by procuring equipment for production. A collaboration with Johns Hopkins University continues under a National Institutes of Health grant investigating the technology as a smoking cessation alternative, although funding for clinical trials is still pending. The company clarified that its manufacturing and commercialization schedule is not contingent on this NIH decision.

The company recently reached a scientific milestone with the acceptance of a peer-reviewed manuscript for publication on December 15, 2025. The paper, co-authored by scientist Dr. Katharine Cole and founder Dr. Pankaj Modi, offers a thorough review of micelle and oral dissolvable strip technology research. This publication is projected to boost visibility and comprehension of the scientific foundations behind CTT's platform among shareholders, potential partners, and the scientific community. Khouri also highlighted ongoing initiatives to strengthen the company's patent portfolio and plans for a first-quarter conference call to review progress and forthcoming activities. With capital becoming accessible, the company is expanding its team, moving toward manufacturing, and establishing regulatory pathways to introduce its drug delivery technology to the market.